Developer docs
API playgroundTry for free, no card

Search company profiles

AiCure

Full company profile

uuid0000bdh

Namestring
AiCure
Legal namestring
AICure Corporation
Websiteurl
aicure.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

AiCure (legal entity AICure Corporation) is a New York-domiciled, private healthcare AI company founded in 2009/2010 that built H.Code, the first AI-powered medication adherence verification platform for clinical trials. H.Code uses proprietary computer vision, predictive analytics, and behavioral digital biomarker capture — via smartphone only, with no wearables or invasive hardware — to verify that the right patient takes the right medication at the right time, and to predict early termination risk (the first 14 days of adherence data are predictive of study completion). The platform is deployed across 2,200+ clinical trial sites in 46 countries and 45 languages, has captured 1.5M+ participant doses across 223+ studies spanning 15+ therapeutic areas, and serves 7 of the top 10 global pharmaceutical companies. Revenue is generated through quote-based, multi-year enterprise SaaS subscriptions to pharmaceutical, biotechnology, and CRO customers, supplemented by Clinical Site Services (CSS) professional services revenue. Go-to-market combines direct enterprise field sales (Account Directors at $145K-$165K), inside sales (SDRs), and a formal CRO channel program (AiPEX) with partners including Science 37, Qwince (Italy), OncoBay, IMA Group, and Recognify. The company holds 84 awarded patents (30 pending) and is compliant with 21 CFR Part 11, HIPAA, GDPR, SOC 2 Type 2, and ISO 27001. Following a leadership transition in May 2025 (Sabina Chadha appointed CEO; Ed Ikeguchi moved to CMO; Josh Wilson promoted to COO/President), AiCure was acquired by Vive VC, a healthcare-focused investment firm.

Short descriptiontext

AiCure is a private healthcare AI company that sells the H.Code platform — using computer vision and predictive analytics to verify medication adherence and capture digital biomarkers in clinical trials — to pharmaceutical, biotech, and CRO customers across 46 countries, with 7 of the top 10 global pharma as customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial software, medication adherence verification, digital biomarkers platform, patient engagement AI, eCOA ePRO solutions
Industry3 codes
PRIMARYHLACAEAJ
Adherence, Reminders & Engagement Automation (Medication/Follow-up)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLALAIAD
ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLACAIAG
Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
NAICS code2 codes
  • Software Publishers513210
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Trial Technology / Digital Health AI
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI-Powered Medication Adherence Platform (H.Code)
TypeSubscription Recurring
Description

SaaS platform subscription model providing medication adherence verification, patient engagement, and digital biomarker capabilities to pharmaceutical companies, biotech firms, and CROs for clinical trials. Revenue generated through platform licensing, implementation services, and ongoing support.

aicure.com
2Clinical Site Services
TypeProfessional Services
Description

End-to-end clinical site support services including monitoring of adherence metrics, compliance tracking, and data management support for clinical trials.

aicure.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise platform licensing for pharmaceutical companies and CROs
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based pricing tailored to enterprise requirements. AiCure serves 7 of top 10 global pharma companies indicating enterprise-level pricing contracts.

aicure.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1H.Code
Description

AI-powered patient engagement and adherence verification platform trusted by pharma, CROs, and providers to verify medication and clinical behavior adherence.

aicure.com
+4 more records
Core offering1 text field

AiCure builds and licenses H.Code, an AI-powered medication adherence verification and patient engagement platform for clinical trials, using computer vision, synchronous chat, and predictive analytics on a smartphone to confirm that the right patient takes the right medication at the right time. The platform also captures digital biomarkers, supports eCOA/ePRO, and is complemented by Clinical Site Services for site monitoring, generating revenue primarily through multi-year enterprise SaaS subscriptions plus professional services for pharmaceutical, biotech, and CRO customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 92% participant retention rate
+5 more records
Product overview1 text field

AiCure offers H.Code, an AI-powered patient engagement and medication adherence verification platform for life sciences. The platform consists of multiple integrated modules: Patient Connect for medication reminders and engagement, Digital Phenotypes for capturing digital biomarkers, Site Services for clinical site support, AiCurator for data management, Clinical Site Dashboards for performance visibility, and eCOA/ePRO for patient-reported outcomes. The platform uses computer vision and predictive analytics to verify medication adherence and predict trial outcomes through smartphone-based observation.

Product and service3 records
1H.Code Platform
CategoryClinical Trial AI Platform / Medication Adherence Software
Description

AI-powered patient engagement and medication adherence verification platform that uses computer vision, synchronous chat, and predictive analytics through a smartphone to verify that the right patient takes the right medication at the right time, capture digital biomarkers, support eCOA/ePRO, and predict early termination risk across site-based, decentralized, fully virtual, and hybrid clinical trials. Sold to pharmaceutical sponsors, biotech firms, CROs, and clinical trial sites globally.

2Clinical Site Services (CSS)
CategoryClinical Trial Professional Services
Description

Professional services offering providing clinical trial sites with end-to-end, customized support and monitoring of adherence, compliance, data management, and technology-use metrics, delivering actionable data-driven guidance and contributing to early termination rates as low as 7.8% across 28 Phase I-IV studies with over 4,000 patients.

3OpenDBM (Open Digital Biomarker Platform)
CategoryOpen-Source Digital Biomarker Platform
Description

Open-source platform that allows researchers to apply AiCure's digital biomarker algorithms to their own datasets, supporting academic and translational research use cases for digital phenotyping and behavioral biomarker development.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-12
Description

DHA PTSD-DT Program deploying AiCure's AI platform in PTSD adaptive platform trial to simultaneously evaluate efficacy of multiple PTSD treatments in active service members and veterans. AiCure provides medication adherence platform and digital biomarker solution.

Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2022-04-05
Description

Italy-based technology and services company focused on helping organizations implement innovative solutions and advance healthcare. Partnership aims to foster clinical and commercial opportunities for deployment of AiCure's AI platform with pharmaceutical sponsors and government healthcare departments in Italy.

Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2021-03-15
Description

Partnership to optimize clinical trial recruitment and patient engagement through combined expertise in patient recruitment and AI-powered adherence monitoring.

4OncoBay Clinical
Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2021-02-24
Description

Partnership to improve oncology clinical trials and patient care through integration of AiCure's patient engagement and adherence verification with OncoBay's oncology-focused clinical services.

aicure.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-04-30
Description

Partnership to enhance virtual clinical trials by integrating AiCure's medication adherence and patient engagement technology with Science 37's decentralized clinical trial platform.

6Recognify Life Sciences
Strategic tierRegionalTypeStrategic or Co-development Partner
Description

Partnership using AiCure medication adherence technology for cognitive deficit studies. Recognify focuses on mental health and cognitive therapeutic areas with innovative approaches to improving medication adherence.

info.aicure.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership selected as finalist for 2021 Citeline Award for Best Use of AI in Clinical Trials. Collaboration on AI-powered clinical trial optimization.

8Various CRO Partners (AiPEX)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

AiPEX (AiCure Partnerships for Excellence) is a formal CRO partnership program enabling partners to leverage AiCure's platform of Medication Adherence and Predictive Insights, Digital Biomarkers, and ePRO products to offer higher quality data and robust insights for faster and smaller clinical trials.

aicure.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medidata (a Dassault Systèmes company) is a leading eClinical platform offering EDC, eCOA/ePRO, CTMS, and patient engagement tools. It directly competes with AiCure's H.Code in eCOA and patient engagement modules and is a more established suite for pharma sponsors.

TypeBroad incumbent
Description

Veeva's Vault Clinical Suite covers CTMS, eTMF, and clinical operations, with ePRO and patient engagement capabilities. It targets the same large pharma customer base as AiCure and competes on platform breadth rather than AI depth.

TypeDirect peer
Description

Clario (formed from ERT and Bioclinica) provides eCOA, cardiac safety, imaging, and patient-centric clinical trial technology. It directly overlaps with AiCure's adherence and ePRO offerings for global pharma sponsors and CROs.

TypeDirect peer
Description

Science 37 is a decentralized clinical trial platform and an AiPEX partner of AiCure. It competes in the DCT space where AiCure also plays, though primarily as an integrated partner rather than a head-to-head rival on adherence.

TypeDirect peer
Description

Medable provides a decentralized trial platform including eCOA, ePRO, telehealth, and patient engagement. It targets the same pharma and CRO buyers as AiCure with a broader DCT-focused suite.

6Biofourmis
TypeDirect peer
Description

Biofourmis applies AI and wearable/sensor data to clinical trial endpoints and post-market patient monitoring. It overlaps with AiCure's digital biomarker and predictive analytics capabilities, particularly in decentralized and post-approval settings.

TypeDirect peer
Description

Castor is an eClinical platform offering EDC, ePRO, and DCT tools, including an AI assistant for protocol design. It targets the same pharma/biotech and CRO segments as AiCure with an emphasis on mid-market and academic trials.

TypeDirect peer
Description

ObvioHealth is a DCT-focused CRO and technology provider with its own patient app and eCOA capabilities. It competes in the same adherence and patient engagement categories for global sponsors running decentralized studies.

TypeDirect peer
Description

Thread Research provides a decentralized clinical trial platform with patient engagement and data capture tools for pharma sponsors. It competes with AiCure on DCT-enabled trial execution and remote data collection.

TypeBroad incumbent
Description

IQVIA combines CRO services with the Orchestrated Patient Engagement suite and eCOA technology, serving large pharma sponsors. It is a broader incumbent competing against AiCure on patient engagement, adherence, and trial technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AiCure

Clinical Trial Technology / Digital Health AIaicure.com

AiCure is a private healthcare AI company that sells the H.Code platform — using computer vision and predictive analytics to verify medication adherence and capture digital biomarkers in clinical trials — to pharmaceutical, biotech, and CRO customers across 46 countries, with 7 of the top 10 global pharma as customers.

What AiCure does

AiCure (legal entity AICure Corporation) is a New York-domiciled, private healthcare AI company founded in 2009/2010 that built H.Code, the first AI-powered medication adherence verification platform for clinical trials. H.Code uses proprietary computer vision, predictive analytics, and behavioral digital biomarker capture — via smartphone only, with no wearables or invasive hardware — to verify that the right patient takes the right medication at the right time, and to predict early termination risk (the first 14 days of adherence data are predictive of study completion). The platform is deployed across 2,200+ clinical trial sites in 46 countries and 45 languages, has captured 1.5M+ participant doses across 223+ studies spanning 15+ therapeutic areas, and serves 7 of the top 10 global pharmaceutical companies. Revenue is generated through quote-based, multi-year enterprise SaaS subscriptions to pharmaceutical, biotechnology, and CRO customers, supplemented by Clinical Site Services (CSS) professional services revenue. Go-to-market combines direct enterprise field sales (Account Directors at $145K-$165K), inside sales (SDRs), and a formal CRO channel program (AiPEX) with partners including Science 37, Qwince (Italy), OncoBay, IMA Group, and Recognify. The company holds 84 awarded patents (30 pending) and is compliant with 21 CFR Part 11, HIPAA, GDPR, SOC 2 Type 2, and ISO 27001. Following a leadership transition in May 2025 (Sabina Chadha appointed CEO; Ed Ikeguchi moved to CMO; Josh Wilson promoted to COO/President), AiCure was acquired by Vive VC, a healthcare-focused investment firm.

AiCure firmographics

Firmographics
Name
AiCure
Legal name
AICure Corporation
Website
https://aicure.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
AiCure is a private healthcare AI company that sells the H.Code platform — using computer vision and predictive analytics to verify medication adherence and capture digital biomarkers in clinical trials — to pharmaceutical, biotech, and CRO customers across 46 countries, with 7 of the top 10 global pharma as customers.
Ownership category
akta.pro rank

AiCure industry classification

Industry
Product category
Clinical Trial Technology / Digital Health AI
NAICS
Software Publishers (513210), Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAEAJ
Adherence, Reminders & Engagement Automation (Medication/Follow-up)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLALAIAD
ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLACAIAG
Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance

Keywords

  • Clinical trial software
  • Medication adherence verification
  • Digital biomarkers platform
  • Patient engagement AI
  • ECOA ePRO solutions

Where AiCure is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

AiCure business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI-Powered Medication Adherence Platform (H.Code): SaaS platform subscription model providing medication adherence verification, patient engagement, and digital biomarker capabilities to pharmaceutical companies, biotech firms, and CROs for clinical trials. Revenue generated through platform licensing, implementation services, and ongoing support.
  2. Clinical Site Services: End-to-end clinical site support services including monitoring of adherence metrics, compliance tracking, and data management support for clinical trials.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise platform licensing for pharmaceutical companies and CROs

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

AiCure product offering

Product offering

Core offering

AiCure builds and licenses H.Code, an AI-powered medication adherence verification and patient engagement platform for clinical trials, using computer vision, synchronous chat, and predictive analytics on a smartphone to confirm that the right patient takes the right medication at the right time. The platform also captures digital biomarkers, supports eCOA/ePRO, and is complemented by Clinical Site Services for site monitoring, generating revenue primarily through multi-year enterprise SaaS subscriptions plus professional services for pharmaceutical, biotech, and CRO customers.

Product overview

AiCure offers H.Code, an AI-powered patient engagement and medication adherence verification platform for life sciences. The platform consists of multiple integrated modules: Patient Connect for medication reminders and engagement, Digital Phenotypes for capturing digital biomarkers, Site Services for clinical site support, AiCurator for data management, Clinical Site Dashboards for performance visibility, and eCOA/ePRO for patient-reported outcomes. The platform uses computer vision and predictive analytics to verify medication adherence and predict trial outcomes through smartphone-based observation.

Differentiator

Problem solved

Functional benefit

Brands

  • H.Code: AI-powered patient engagement and adherence verification platform trusted by pharma, CROs, and providers to verify medication and clinical behavior adherence.
  • Patient Connect
  • AiCurator
  • Digital Phenotypes
  • OpenDBM

Products and services

  • H.Code Platform AI-powered patient engagement and medication adherence verification platform that uses computer vision, synchronous chat, and predictive analytics through a smartphone to verify that the right patient takes the right medication at the right time, capture digital biomarkers, support eCOA/ePRO, and predict early termination risk across site-based, decentralized, fully virtual, and hybrid clinical trials. Sold to pharmaceutical sponsors, biotech firms, CROs, and clinical trial sites globally.
  • Clinical Site Services (CSS) Professional services offering providing clinical trial sites with end-to-end, customized support and monitoring of adherence, compliance, data management, and technology-use metrics, delivering actionable data-driven guidance and contributing to early termination rates as low as 7.8% across 28 Phase I-IV studies with over 4,000 patients.
  • OpenDBM (Open Digital Biomarker Platform) Open-source platform that allows researchers to apply AiCure's digital biomarker algorithms to their own datasets, supporting academic and translational research use cases for digital phenotyping and behavioral biomarker development.

Quantifiable outcome

  • 92% participant retention rate
  • +5 more outcomes

Companies that use AiCure

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

AiCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

AiCure partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and regional.

  • Defense Health Agency (DHA)coreStrategic or Co-development Partner · 12 July 2022DHA PTSD-DT Program deploying AiCure's AI platform in PTSD adaptive platform trial to simultaneously evaluate efficacy of multiple PTSD treatments in active service members and veterans. AiCure provides medication adherence platform and digital biomarker solution.
  • QwinceregionalStrategic or Co-development Partner · 5 April 2022Italy-based technology and services company focused on helping organizations implement innovative solutions and advance healthcare. Partnership aims to foster clinical and commercial opportunities for deployment of AiCure's AI platform with pharmaceutical sponsors and government healthcare departments in Italy.
  • The IMA GroupregionalStrategic or Co-development Partner · 15 March 2021Partnership to optimize clinical trial recruitment and patient engagement through combined expertise in patient recruitment and AI-powered adherence monitoring.
  • OncoBay ClinicalregionalStrategic or Co-development Partner · 24 February 2021Partnership to improve oncology clinical trials and patient care through integration of AiCure's patient engagement and adherence verification with OncoBay's oncology-focused clinical services.
  • Science 37coreTechnology or Integration · 30 April 2020Partnership to enhance virtual clinical trials by integrating AiCure's medication adherence and patient engagement technology with Science 37's decentralized clinical trial platform.
  • Recognify Life SciencesregionalStrategic or Co-development PartnerPartnership using AiCure medication adherence technology for cognitive deficit studies. Recognify focuses on mental health and cognitive therapeutic areas with innovative approaches to improving medication adherence.
  • MerckcoreStrategic or Co-development PartnerPartnership selected as finalist for 2021 Citeline Award for Best Use of AI in Clinical Trials. Collaboration on AI-powered clinical trial optimization.
  • Various CRO Partners (AiPEX)coreChannel Partner/ Reseller/ DistributorAiPEX (AiCure Partnerships for Excellence) is a formal CRO partnership program enabling partners to leverage AiCure's platform of Medication Adherence and Predictive Insights, Digital Biomarkers, and ePRO products to offer higher quality data and robust insights for faster and smaller clinical trials.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

AiCure competitors and assessment

Company assessment

Broad incumbents

  • Medidata Solutions: Medidata (a Dassault Systèmes company) is a leading eClinical platform offering EDC, eCOA/ePRO, CTMS, and patient engagement tools. It directly competes with AiCure's H.Code in eCOA and patient engagement modules and is a more established suite for pharma sponsors.
  • Veeva Systems: Veeva's Vault Clinical Suite covers CTMS, eTMF, and clinical operations, with ePRO and patient engagement capabilities. It targets the same large pharma customer base as AiCure and competes on platform breadth rather than AI depth.
  • IQVIA: IQVIA combines CRO services with the Orchestrated Patient Engagement suite and eCOA technology, serving large pharma sponsors. It is a broader incumbent competing against AiCure on patient engagement, adherence, and trial technology.

Direct peers

  • Clario: Clario (formed from ERT and Bioclinica) provides eCOA, cardiac safety, imaging, and patient-centric clinical trial technology. It directly overlaps with AiCure's adherence and ePRO offerings for global pharma sponsors and CROs.
  • Science 37: Science 37 is a decentralized clinical trial platform and an AiPEX partner of AiCure. It competes in the DCT space where AiCure also plays, though primarily as an integrated partner rather than a head-to-head rival on adherence.
  • Medable: Medable provides a decentralized trial platform including eCOA, ePRO, telehealth, and patient engagement. It targets the same pharma and CRO buyers as AiCure with a broader DCT-focused suite.
  • Biofourmis: Biofourmis applies AI and wearable/sensor data to clinical trial endpoints and post-market patient monitoring. It overlaps with AiCure's digital biomarker and predictive analytics capabilities, particularly in decentralized and post-approval settings.
  • Castor: Castor is an eClinical platform offering EDC, ePRO, and DCT tools, including an AI assistant for protocol design. It targets the same pharma/biotech and CRO segments as AiCure with an emphasis on mid-market and academic trials.
  • ObvioHealth: ObvioHealth is a DCT-focused CRO and technology provider with its own patient app and eCOA capabilities. It competes in the same adherence and patient engagement categories for global sponsors running decentralized studies.
  • Thread Research: Thread Research provides a decentralized clinical trial platform with patient engagement and data capture tools for pharma sponsors. It competes with AiCure on DCT-enabled trial execution and remote data collection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

AiCure social profiles

Digital presence

AiCure compliance and trust

Trust signal

Compliance6 records

AiCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AiCure leadership team

Management profile

Number of profiles

Profiles12 records

AiCure funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AiCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AiCure

What does AiCure do?

AiCure builds and licenses H.Code, an AI-powered medication adherence verification and patient engagement platform for clinical trials, using computer vision, synchronous chat, and predictive analytics on a smartphone to confirm that the right patient takes the right medication at the right time. The platform also captures digital biomarkers, supports eCOA/ePRO, and is complemented by Clinical Site Services for site monitoring, generating revenue primarily through multi-year enterprise SaaS subscriptions plus professional services for pharmaceutical, biotech, and CRO customers.

Is AiCure a public or private company?

AiCure is a private company. It is classified as venture growth investor backed and is currently operating.

When was AiCure founded?

AiCure was founded in 2010. It employs 11 to 50 people.

Where is AiCure based?

AiCure is headquartered in Houston, United States, in the North America region.

How does AiCure make money?

Two revenue lines are on record. AI-Powered Medication Adherence Platform (H.Code) is the primary driver. The others are clinical Site Services.

Who are AiCure's main competitors?

Broad incumbents on record are Medidata Solutions, Veeva Systems and IQVIA. Direct peers are Clario, Science 37, Medable, Biofourmis, Castor, ObvioHealth and Thread Research.

Does AiCure have an API?

No public API is recorded for AiCure.

What industry is AiCure in?

AiCure's product category is Clinical Trial Technology / Digital Health AI. Its primary akta.pro industry code is HLACAEAJ, Adherence, Reminders & Engagement Automation (Medication/Follow-up), with a secondary code of HLALAIAD, ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tracxn2026 Funding Rounds & List of InvestorsAiCure's funding rounds from 2011 to 2024 are listed, including Series A through Series C and a conventional debt round. The rounds show increasing post-money valuations, with the most recent round on January 23, 2024, raising $28,398,410.citybizAICure Appoints Anand Ramaswamy Chief Product Officer and Olinka Greene Director of Quality Assurance to Expand AI Healthcare PlatformAICure has appointed Anand Ramaswamy as Chief Product Officer and Olinka Greene as Director of Quality Assurance to support expansion of its AI-powered healthcare technology platform. The leadership additions coincide with the launch of WeightVerify, a remote weight verification solution, and expansion of white-label offerings for pharmaceutical companies, healthcare providers, and biotechnology firms. CEO Sabina Chadha stated the appointments reinforce AICure's strategy of advancing AI innovation while maintaining regulatory compliance as healthcare increasingly shifts toward digital care delivery.ForbesThe AI Company Transforming Medication Adherence And Weight LossAiCure, an AI-driven healthcare solutions provider, has been acquired by Silicon Valley venture capital firm Vive VC and is expanding its platform with the WeightVerify™ tool for remote weight monitoring. The company leverages computer vision to verify medication adherence and patient data, currently partnering with seven of the world's leading pharmaceutical companies to support clinical trials and chronic disease management.DLA PiperArtificial Intelligence and Data Analytics LawyersThe article serves as a service overview for a legal firm specializing in Artificial Intelligence and Data Analytics, highlighting their capabilities in regulatory compliance, litigation, and corporate transactions. It lists specific client engagements involving companies such as AiCure, Capital One, and Intuit to demonstrate expertise in AI-related legal matters. The text emphasizes the firm's role in helping clients navigate global regulations, ethical standards, and emerging technologies.PR NewswireAiCure Appoints Sabina Chadha as CEO, Ed Ikeguchi Transitions to Chief Medical Officer, and Josh Wilson Promoted to COO and PresidentAiCure announced leadership changes with Sabina Chadha appointed as new Chief Executive Officer, effective immediately. Ed Ikeguchi, who led the company as CEO since 2020, will transition to the role of Chief Medical Officer to focus on clinical strategy and innovation, including the H.Code platform. Josh Wilson has been promoted from Senior Vice President of Operations to Chief Operating Officer and President, overseeing product strategy and operations.GlobeNewswireAI-Powered Clinical Trial Management Market Forecasts Report 2024-2029, Profiles of Medidata, Oracle, IBM, Veeva Systems, Clinerion, Saama Technologies, Bioclinica, Arisglobal, Aicure, MedableThe AI-powered clinical trial management market is projected to grow from $1.794 billion in 2024 to $4.950 billion by 2029, a CAGR of 22.50%. Growth is driven by adoption of AI platforms for patient recruitment, data analysis, and protocol optimization, with North America leading.YahooAI-Powered Clinical Trial Management Market Forecasts Report 2024-2029, Profiles of Medidata, Oracle, IBM, Veeva Systems, Clinerion, Saama Technologies, Bioclinica, Arisglobal, Aicure, MedableThe AI-powered clinical trial management market is projected to grow from $1.794 billion in 2024 to $4.950 billion by 2029, a CAGR of 22.50%. Growth is driven by adoption by pharmaceutical companies and research institutions, with North America expected to see exponential growth.Business Wire BlogAiCure Bringing New Patient Engagement Platform H.Code to DPHARM 2024AiCure will launch its H.Code patient engagement platform at DPHARM 2024, combining computer vision, app-based communication, and predictive analytics. CEO Ed Ikeguchi will speak on streamlining trial participation with a single platform, and the company promoted Josh Wilson to COO.Rolling OutEarnest Offley leading the way to inclusive innovationEarnest Offley, Chief People and Diversity Officer at AiCure, leads inclusive innovation by integrating DEI with HR and developing unbiased AI for clinical trials. He corrected AI bias in skin tone recognition, aligning with FDA requirements for diverse action plans. He aims to make this technology an enterprise standard across pharmaceutical and clinical research organizations.PR NewswireAiCure Raises Funds, Secures New Patents, and Bolsters Leadership TeamAiCure completed a $12M loan refinancing and raised an additional $4M+ from existing investors. The company also secured seven new US patents, bringing its total to 86, and added two senior executives to its leadership team. The funding will support R&D, operations, and product expansion.